Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer (AVIAS)

Canadian Urology Research Consortium

Status and phase: Completed; Phase 3; Phase 2

Conditions: Prostate Cancer

Treatments: Drug: Dutasteride

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00553878

CURC/CUOG-AVIAS-0601

Details and patient eligibility

About

Patient on an intermittent androgen deprivation protocol for biochemical recurrence after radical local therapy for prostate cancer,the addition of continuous dutasteride treatment, significantly prolongs the duration of the off treatment interval and time to androgen independence.

Full description

The study is to assess the effect of therapy with repeat oral daily dosing of dutasteride 05 mg on the length of the off treatment interval in men receiving intermittent androgen therapy for localized prostate cancer.

Enrollment: 100 estimated patients

Sex: Male

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to give informed consent
• Age_>45and<_80
• Histological confirmed adenocarcinoma of prostate
• Has received external beam radiation,brachytherapy or radical prostatectomy for the treatment of prostate ca
• Candidate for intermittent androgen ablation
• Minimum of 3 PSA values above nadir taken at least 1 month apart
• Serum testosterone >_250ng/dl,ECOG 0 or 1
• Negative bone scan within 12 months of visit 1
• Able to swallow and retain oral medication

Exclusion criteria

• Previous treatment with chemotherapy
• Hormonal therapy with in last year
• Glucocorticoid with in last 3 months
• LHRH analogues with in previous year
• Ketoconazole
• Non Steroidal anti-androgens with in previous year
• Concurrent or previous use of Finasteride Dutasteride 5a reductase inhibitor anabolic steroids
• Over the counter or herbal prep such as saw palmetto selenium or vitamin E within last year
• May not be receiving any other investigational drug with in last 30 days
• Evidence of distant metastases
• Has received adjuvant or neoadjuvant ablation in past 12 months
• Unstable serious co-existing medical condition
• Abnormal liver and kidney functions
• Previous malignancy not including curative treated basal cell carcinoma of skin with in 5 years and bladder cancer with in past 2 years
• Known hypersensitivity to any 5a-reductase inhibitor or to any drug chemically related to dutasteride
• Known hypersensitivity to bicalutamide.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

100 participants in 1 patient group, including a placebo group

dutasteride

Placebo Comparator group

Treatment:

Drug: Dutasteride